Aims The treatment with the wearable cardioverter defibrillator (WCD) may protect against sudden cardiac death (SCD) as a bridging therapy until a cardioverter defibrillator may be implanted. Data regarding the impact of WCD on the outcome of patients according gender differences are limited. We analysed a consecutive patient cohort wearing WCD to explore gender differences. Methods and results We analysed 153 consecutive patients of whom were 118 males and 35 females (age, 60±13 vs. 60±16 years old; p=0.88). More males receiving WCD as compared to females suffered from ischemic cardiomyopathy (ICM) (41% vs. 23%; p=0.05), while females were diagnosed with non-ischemic cardiomyopathy (NICM) (60% vs. 42%); p=0.05). The wear time of WCD was equivalent in both groups (21±4 in males vs. 22±3 hours/days in females; p=0.18; and 65±42 in males vs. 65±43 days in females; p=0.96). In both groups, the left ventricular ejection fraction (LVEF) improved in males from 29±10% to 41±12% and in females from 28±12% to 45±13%; p=0.12. At 6-12 month-follow-up, the LVEF increased more in females as compared to males (40% vs. 17%; p=0.003). The rate of rehospitalization due to cardiovascular cause and all-cause-mortality were comparable in both groups at 6-12 month-follow-up (55% in male vs. 54% in female group; p=0.93) (9% in male vs. 11% in female group; p=0.71). Conclusion Compliance for wearing of WCD was excellent regardless of gender. During follow-up, LVEF improved more in females as compared to males. All-cause mortality and the rate of rehospitalization were comparable in both groups.